Defendant

Avadel CNS Pharmaceuticals, LLC

9 cases as defendant.

Cases
9
Active
1
8 closed
Filed
2021–2022
Top venue
D. Delaware
3 cases
Also appears as a plaintiff in 9 cases → View as plaintiff

Company profile

Avadel CNS Pharmaceuticals, LLC is a Delaware limited liability company and a wholly owned subsidiary of Avadel US Holdings, Inc., which is in turn wholly owned by Avadel Pharmaceuticals plc (Nasdaq: AVDL), an Irish public limited company. Its U.S. principal place of business is 16640 Chesterfield Grove Road, Chesterfield, Missouri; the parent is headquartered in Dublin, Ireland. Avadel plc was incorporated in Ireland in December 2015 as successor to Flamel Technologies (founded 1990) and took its current name in January 2017. Per its FY2024 Form 10-K, Avadel plc reported approximately 188 employees and $169.1 million in net product revenue, with a net loss of $48.8 million; market capitalization was reported near $1.4 billion in 2024.

Avadel CNS is the entity holding and developing the company's narcolepsy franchise. Its sole commercial product is LUMRYZ (sodium oxybate), an extended-release, once-nightly formulation approved by the FDA in May 2023 for cataplexy or excessive daytime sleepiness in adults with narcolepsy, and in October 2024 for patients aged seven and older. LUMRYZ uses the parent's proprietary Micropump drug-delivery technology, is dispensed through a restricted REMS distribution program, and is sold to specialty pharmacies. The parent previously marketed hospital injectables but has since refocused on sleep medicine. This is an operating company, not a patent assertion entity.

Litigation posture: Avadel CNS is an active two-way litigant — 9 tracked plaintiff cases and 9 defendant cases — dominated by Hatch-Waxman/Orange Book disputes rather than NPE-style assertion. Venues are the District of Delaware, the District of Columbia, the District of New Jersey, and the Federal Circuit; no Eastern District of Texas filings appear in the tracked data.

Notable matters: Jazz Pharmaceuticals sued Avadel CNS repeatedly (2021–2022) over sodium oxybate patents, including a REMS-distribution patent later delisted from the Orange Book; a February 2024 Delaware jury awarded Jazz roughly $233,562.83 on one process patent. Avadel CNS counterclaimed with Sherman Act claims over the Orange Book listing and filed its own infringement suits against Jazz in 2023 and 2025. Avadel also sued HHS Secretary Becerra in D.D.C. (2022) over its FDA application, and in July 2026 filed against Granules India Limited in New Jersey. The parties announced a global settlement in October 2025.

Filing activity

2021: 6 cases6'212022: 2 cases'22
Cases filed per year naming Avadel CNS Pharmaceuticals, LLC as defendant.

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

dismissed
Docket:
1:22-cv-00941-GBW
Filed:
2022-07-15
Terminated:
2023-03-07
Patents:8731963

Fourth Jazz Complaint re-asserting U.S. 8,731,963 after FDA required Avadel to file a Paragraph IV certification. Avadel counterclaimed for non-infringement, invalidity, delisting, and Sherman Act monopolization. The case was dismissed by stipulation on March 7, 2023.

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

dismissed with prejudice (settled)
Docket:
1:22-cv-00941-GBW
Filed:
2022-07-15
Terminated:
2025-10-27
Patents:11147782

Fourth Jazz complaint/antitrust case involving Jazz's listing of the '963 (REMS) patent and Avadel's Sherman Act counterclaims. Jazz moved to stay pending final resolution of the validity of U.S. Patent No. 11,147,782. Dismissed with prejudice on October 27, 2025 pursuant to settlement.

Jazz Pharmaceuticals, Inc. et al. v. Avadel CNS Pharmaceuticals, LLC et al.

dismissed with prejudice
Docket:
1:21-cv-01594-GBW
Filed:
2021-11-10
Terminated:
2025-10-27
Patents:10272062

Patent infringement action involving Jazz Pharmaceuticals entities and Avadel entities; resolved in the same October 2025 global settlement and stipulation of dismissal with prejudice entered October 27, 2025.

Jazz Pharmaceuticals, Inc. et al. v. Avadel CNS Pharmaceuticals, LLC

consolidated; '963 claims dismissed; other patents proceeded
Docket:
1:21-cv-00691-GBW
Filed:
2021-05-12

First Jazz Complaint in D. Del. over Avadel's FT218/LUMRYZ. The consolidated action asserted five patents, including U.S. 8,731,963. The court held the '963 claims directed to systems, not methods, and ordered Jazz to request delisting from the Orange Book; on March 7, 2023, the '963 infringement claims and related counterclaims were dismissed by stipulation. Other patents, including U.S. 10,758,488 and 11,147,782, proceeded to a 2024 jury verdict.

Jazz Pharmaceuticals, Inc. et al. v. Avadel CNS Pharmaceuticals, LLC et al.

dismissed
Docket:
1:21-cv-00691-GBW
Filed:
2021-05-12
Terminated:
2025-10-27
Patents:10952986

Jazz-side Delaware action in the Avadel–Jazz once-nightly sodium oxybate dispute. The '986 patent appeared on the patent lists in connection with Avadel's counterclaims and inequitable-conduct/derivation allegations concerning Flamel's '321 application and Jazz's '079/'782 patents. The case was resolved by the October 2025 settlement and dismissed with prejudice on 2025-10-27.

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

dismissed with prejudice
Docket:
1:21-cv-00691-GBW
Filed:
2021-05-12
Terminated:
2025-10-27
Patents:10272062

Patent infringement action by Jazz Pharmaceuticals against Avadel CNS Pharmaceuticals concerning sodium oxybate/LUMRYZ; consolidated with related actions and resolved by a global settlement and stipulation of dismissal with prejudice entered October 27, 2025.

Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC

terminated
Court:
D. Del.
Filed:
2021-05-12
Terminated:
2025-10-27
Patents:10213400

DrugPatentWatch lists the '400 patent in this Avadel matter; the exact case number and whether the '400 patent was actually asserted could not be independently confirmed. It is listed as terminated Oct 27, 2025.